# Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Source: https://onco.cc/trials/nct04273061/  
OnCo record `nct04273061` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of atezolizumab in lung cancer, run by British Columbia Cancer Agency, now recruiting.

## Summary

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity is a phase 2, interventional study registered as NCT04273061 by British Columbia Cancer Agency, with a registry enrolment figure of 50 participants, started 2020-06-17 and due to reach its primary completion in 2027-10. Interventions recorded: Atezolizumab. Conditions listed: Breast Cancer; Lung Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Gynecologic Cancer; Sarcoma; Unknown Primary Tumors; Head and Neck Cancer; Skin Cancer. Primary outcome: Overall response rate (ORR) for the study cohort, as defined by RECIST 1.1. Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: CAPTIV-8
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04273061
- Phase: 2
- Setting: Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
- Sponsor: British Columbia Cancer Agency
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04273061: https://clinicaltrials.gov/study/NCT04273061

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04273061.json